SPX4,280.15+72.88 1.73%
DIA337.83+4.12 1.23%
IXIC13,047.19+267.27 2.09%

Ionis Announces Topline Results From Phase 2b Clinical Study Of Fesomersen; Says Phase 2b Re-thinc Esrd Study Of Fesomersen Met Its Primary Endpoint

Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in

Benzinga · 07/28/2022 07:09
  • Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis
  • Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels
    • Fesomersen, a novel Factor XI antisense inhibitor designed to prevent thrombosis, was safe and well-tolerated in the study with up to 48-week treatment